HC Wainwright Issues Positive Estimate for BioNTech Earnings

BioNTech SE Sponsored ADR (NASDAQ:BNTX) – Research analysts at HC Wainwright increased their Q4 2026 earnings per share estimates for shares of BioNTech in a research report issued on Wednesday, December 10th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of $1.14 for the quarter, up from their prior estimate of $1.13. HC Wainwright has a “Buy” rating and a $140.00 price objective on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, November 3rd. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). The business had revenue of $1.78 billion during the quarter, compared to analyst estimates of $1.21 billion. BioNTech had a negative net margin of 17.91% and a negative return on equity of 3.03%. BioNTech’s quarterly revenue was up 22.0% on a year-over-year basis. During the same quarter last year, the company earned $0.81 earnings per share.

BNTX has been the topic of several other research reports. Cowen reissued a “hold” rating on shares of BioNTech in a research report on Monday, November 3rd. Berenberg Bank increased their price target on shares of BioNTech from $150.00 to $155.00 and gave the company a “buy” rating in a research note on Thursday. Morgan Stanley reiterated an “overweight” rating and issued a $134.00 price objective on shares of BioNTech in a research report on Monday, November 3rd. Bank of America decreased their price target on BioNTech from $134.00 to $130.00 and set a “buy” rating on the stock in a research note on Wednesday, October 22nd. Finally, JPMorgan Chase & Co. lowered their target price on shares of BioNTech from $121.00 to $120.00 and set a “neutral” rating for the company in a research note on Thursday, October 23rd. Ten investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and an average price target of $137.75.

BioNTech Trading Down 1.2%

BNTX opened at $94.81 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.12 and a quick ratio of 7.02. The company’s 50 day simple moving average is $102.27 and its two-hundred day simple moving average is $105.04. The firm has a market capitalization of $21.35 billion, a price-to-earnings ratio of -36.05 and a beta of 1.30. BioNTech has a 1-year low of $81.20 and a 1-year high of $129.27.

Hedge Funds Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Krensavage Asset Management LLC grew its holdings in BioNTech by 8.2% during the 3rd quarter. Krensavage Asset Management LLC now owns 79,366 shares of the company’s stock valued at $7,827,000 after buying an additional 5,984 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its stake in BioNTech by 10.8% during the third quarter. CANADA LIFE ASSURANCE Co now owns 9,552 shares of the company’s stock worth $935,000 after acquiring an additional 933 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of BioNTech in the 3rd quarter valued at about $1,459,000. Alyeska Investment Group L.P. acquired a new stake in BioNTech during the 3rd quarter worth approximately $5,687,000. Finally, Scientech Research LLC acquired a new position in BioNTech during the third quarter valued at approximately $517,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.